Bausch + Lomb subsidiary prices $1.4B 8.375% senior secured notes due 2028

Bausch Health Companies Inc.

Bausch + Lomb subsidiary Bausch + Lomb Escrow Corp. priced $1.4B of 8.375% senior secured notes due 2028.
Notes priced at 100% of principal; exempt from registration under Securities Act and Canadian securities laws.
Proceeds expected to fund pending acquisition of XIIDRA and other ophthalmology assets.
Offering is part of Bausch + Lomb's financing for the acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.